STOCK TITAN

Vaxcyte's Dhaliwal exercises options, sells 17K shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. Chief Technical Ops Officer Harpreet S. Dhaliwal exercised options for 17,000 common shares at $24.79 per share on November 11, 2026, then sold 17,000 shares in three transactions under a Rule 10b5-1 trading plan adopted April 6, 2026. Reported weighted-average sale prices were $67.33 for 7,135 shares, $68.156 for 9,345 shares and $68.819 for 520 shares; the option position after exercise was 11,000 shares.

Insider Dhaliwal Harpreet S.
Role Chief Technical Ops Officer
Sold 17,000 shs ($1.15M)
Approx. gross sale proceeds $1.15M
Approx. exercise cost $421K
Approx. pre-tax spread $732K
Type Security Shares Price Value
Exercise Stock Option (right to buy) F6 17,000 $0.00 $0.00
Exercise Common Stock 17,000 $24.79 $421K
Sale Common Stock F1, F2 7,135 $67.33 $480K
Sale Common Stock F1, F3 9,345 $68.156 $637K
Sale Common Stock F1, F4, F5 520 $68.819 $36K
Holdings After Transaction: Stock Option (right to buy) — 11,000 options (Direct); Common Stock — 68,085 shares (Direct)
Footnotes (6)
  1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 6, 2026.
  2. F2. The price reported is a weighted-average price. The shares were sold at prices ranging from $66.76 to $67.755. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $67.76 to $68.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. F4. The price reported is a weighted-average price. The shares were sold at prices ranging from $68.76 to $68.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. F5. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated October 6, 2026 were sold by the Reporting Person.
  6. F6. Stock Option is fully vested and exercisable.
Options exercised 17,000 shares November 11, 2026
Exercise price $24.79 per share For the exercised options on November 11, 2026
Weighted-average sale price $67.33 per share 7,135 shares; reported prices ranged from $66.76 to $67.755
Weighted-average sale price $68.156 per share 9,345 shares; reported prices ranged from $67.76 to $68.75
Weighted-average sale price $68.819 per share 520 shares; reported prices ranged from $68.76 to $68.85
Option shares following exercise 11,000 shares Expiration date: March 2, 2032
Rule 10b5-1 trading plan regulatory
"sales under a Rule 10b5-1 trading plan adopted April 6, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"Reported weighted-average sale prices"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
fully vested and exercisable technical
"The exercised option was fully vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCVX shares did Harpreet S. Dhaliwal sell, and at what prices?

The three reported sales covered 17,000 shares: 7,135 at a weighted-average $67.33 (prices ranged from $66.76 to $67.755), 9,345 at $68.156 (range $67.76 to $68.75), and 520 at $68.819 (range $68.76 to $68.85). The sales were under a Rule 10b5-1 trading plan adopted April 6, 2026.

What were the terms of Harpreet S. Dhaliwal’s PCVX option exercise?

On November 11, 2026, Dhaliwal exercised options for 17,000 common shares at an exercise price of $24.79 per share. The option was fully vested and exercisable, and 11,000 option shares remained after the transaction, expiring March 2, 2032.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dhaliwal Harpreet S.

(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300

(Street)
SAN CARLOS CALIFORNIA 94070

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technical Ops Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/11/2026M17,000A$24.7985,085D
Common Stock11/11/2026S(1)7,135D$67.33(2)77,950D
Common Stock11/11/2026S(1)9,345D$68.156(3)68,605D
Common Stock11/11/2026S(1)520D$68.819(4)68,085(5)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$24.7911/11/2026M17,000 (6)03/02/2032Common Stock17,000$011,000D
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 6, 2026.
2. The price reported is a weighted-average price. The shares were sold at prices ranging from $66.76 to $67.755. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. The price reported is a weighted-average price. The shares were sold at prices ranging from $67.76 to $68.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
4. The price reported is a weighted-average price. The shares were sold at prices ranging from $68.76 to $68.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
5. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated October 6, 2026 were sold by the Reporting Person.
6. Stock Option is fully vested and exercisable.
Remarks:
Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading